MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS) will announce the preliminary, top-line results of its DeeP-C pivotal clinical trial on Thursday, April 18, 2013, prior to the market open. The company will host a webcast and conference call to discuss the results that morning at 7:30 ET.
The DeeP-C study, one of the largest of its kind, included more than 10,000 patients and evaluated the use of the company’s stool-based DNA screening test for the early detection of colorectal cancer. It was conducted among a population of patients between the ages of 50 and 84 who were at average risk of colorectal cancer. The results of the DeeP-C trial are expected to form the basis of the company’s submission to the U.S. Food and Drug Administration for pre-market approval (PMA) of the convenient, non-invasive test.
DeeP-C Top-line Results Webcast & Conference Call Details
Date: Thursday, April 18, 2013
Time: 7:30 a.m. ET, 6:30 a.m. CT
Webcast:
The live webcast can be accessed at www.exactsciences.com
Telephone: Domestic callers, dial 877-212-6082
International callers, dial 707-287-9332
Access code for both domestic and international callers: 45786044
An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the replay is 45786044. The webcast, conference call and replay are open to all interested parties.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.
Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results and timing of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Contact:
Corporate Communications Contact:
Exact Sciences Corp.
Cara Tucker, 614-302-5622
ctucker@exactsciences.com
or
Media Relations Contact:
Schwartz MSL
Jane Hauser, 781-684-0770
exactsciences@schwartzmsl.com
